아이큐어

175250KOSDAQ의약품 제조업

52.5 / 100

Reference Date: 2026-04-13

Financial Score8.0 / 40

News Sentiment17.5 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PER raises overvaluation concerns. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IQure, established in 2000, specializes in developing transdermal drug delivery systems (TDDS) and pharmaceutical patches, along with OEM/ODM cosmetics. Following the successful Phase III trial of its donepezil patch in 2021, the company has secured global licensing agreements with pharmaceutical giants like Menarini and Celltrion. It also operates an ISO-certified cosmetics manufacturing facility, focusing on skincare OEM/ODM.

Number of Employees

286people

Average Salary

10.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

77.50Industry Average 16.860.0Point

4.6x industry avg (risky)

PBR

1.34Industry Average 1.132.5Point

Higher than industry avg (caution)

ROE

0.04Industry Average 2.941.0Point

Well below industry avg

Debt Ratio

118.80Industry Average 53.870.0Point

2.2x industry avg (risky)

Trend 2022~20244.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.8% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲19.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -21.3% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 70

Positive
아이큐어, 세계 3대 화장품 전시회서 기초 화장품 처방 부문 최종 후보...
아이큐어가 개발한 '스킨 패스팅 엑소좀 세럼'이 세계 3대 화장품 전시회 중 하나인 이탈리아 볼로냐 코스모팩 2026에서 코스모팩 어워드 기초 화장품 처방 부문 4대 최종 후보자로 선정되었습니다.
Positive
아이큐어, '볼로냐 코스모팩 어워드' 기초 처방 부문 최종 후보 선정
아이큐어의 '스킨 패스팅 엑소좀 세럼'이 '이탈리아 볼로냐 코스모팩 어워드' 기초 처방 부문 최종 후보에 선정되었으며, 이는 지난해 다른 전시회에서 코스모팩 어워드 대상을 두 차례 수상한 데 이은 성과입니다.

Detailed Momentum

52-week position8.0Point

Near 52w high (93%, uptrend)

Current 2,170Won52-week high 2,21552-week low 1,517

1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral사업보고서 (2025.12)2026-04-07
Neutral정기주주총회결과2026-03-31
Neutral[기재정정]의결권대리행사권유참고서류2026-03-19
Neutral기타경영사항(자율공시) (감사보고서 지연 제출)2026-03-18
Neutral사업보고서제출기한연장신고서 (2025.12)2026-03-18